Published in J Clin Oncol on August 01, 2011
Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med (2013) 1.69
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer (2015) 1.41
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc (2014) 1.18
Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors (2013) 0.98
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res (2015) 0.97
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med (2013) 0.94
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer (2012) 0.89
Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy. Front Pharmacol (2013) 0.86
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. Biomed Res Int (2015) 0.81
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem (2014) 0.80
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol (2014) 0.80
Heme oxygenase-1 regulates mitochondrial quality control in the heart. JCI Insight (2016) 0.80
Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation (2015) 0.80
Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res (2012) 0.79
Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS One (2016) 0.79
The ineligible patient: how to treat patients not included in clinical studies. World J Urol (2013) 0.78
Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail (2016) 0.78
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer (2016) 0.77
Intersection of cardiology and oncology clinical practices. Front Oncol (2014) 0.77
The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol (2014) 0.77
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer (2014) 0.76
Chemotherapy-induced cardiomyopathy. Heart Fail Rev (2015) 0.76
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. BMJ Case Rep (2013) 0.75
Targeted therapies: Risk of heart failure with sunitinib. Nat Rev Clin Oncol (2011) 0.75
Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis. Medicine (Baltimore) (2016) 0.75
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy. Biomark Cancer (2016) 0.75
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist (2016) 0.75
Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study. J Oncol (2015) 0.75
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res (2017) 0.75
21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine. JACC Basic Transl Sci (2016) 0.75
Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition. Hypertension (2017) 0.75
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A (2002) 4.77
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol (2011) 3.96
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol (2010) 2.80
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology (2011) 2.24
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol (2009) 2.23
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration. Cancer (2015) 2.15
Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circ Res (2007) 2.12
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int (2011) 2.07
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol (2012) 2.00
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol (2012) 1.78
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep (2002) 1.71
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica (2006) 1.67
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Paragangliomas: etiology, presentation, and management. Cardiol Rev (2009) 1.52
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer (2010) 1.52
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res (2006) 1.45
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med (2014) 1.43
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer (2014) 1.41
Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol (2010) 1.36
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol (2010) 1.29
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol (2012) 1.24
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc (2005) 1.22
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer (2010) 1.19
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol (2007) 1.13
Testicular cancer. J Natl Compr Canc Netw (2012) 1.11
Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol (2008) 1.08
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer (2012) 1.07
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer (2012) 1.07
Kidney cancer. J Natl Compr Canc Netw (2011) 1.06
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension (2010) 1.05
Risk of bilateral renal cell cancer. J Clin Oncol (2009) 1.04
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep (2012) 1.03
Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J (2013) 1.00
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00
Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw (2009) 1.00
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys (2011) 1.00
Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate (2011) 1.00
Treatment selection for patients with metastatic renal cell carcinoma. Cancer (2009) 0.99
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. Breast Cancer Res Treat (2013) 0.99
Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin (2010) 0.99
Canadian guideline on genetic screening for hereditary renal cell cancers. Can Urol Assoc J (2013) 0.98
Kidney cancer, version 2.2014. J Natl Compr Canc Netw (2014) 0.98
Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am (2011) 0.98
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer (2014) 0.98
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer (2008) 0.97
Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer (2013) 0.96
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med (2014) 0.95
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw (2011) 0.94